TY - JOUR
T1 - PROSE: Prospective Randomized Trial of the On-X Mechanical Prosthesis and the St Jude Medical Mechanical Prosthesis Evaluation
T2 - Part 2: Study results—prostheses, positions, and economic development
AU - Jamieson, W. R.Eric
AU - Ely, John L.
AU - Brink, Johan
AU - Pennel, Timothy
AU - Bannon, Paul
AU - Patel, Jashvant
AU - Gupta, Rajiv Kumar
AU - Mohan Rao, Prasanna Simha
AU - Agrawal, Damyanti
AU - Wiklund, Lars
AU - Kappetein, A. Pieter
AU - Haaverstad, Rune
AU - Geisner, Thomas
AU - Doenst, Torsten
AU - Schlensak, Christian
AU - Nair, Salgunan
AU - Brown, Craig
AU - Siepe, Matthias
AU - Damiano, Ralph J.
AU - Langlois, Yves
AU - Cherian, Kotturathu M.
AU - Azar, Hormoz
AU - Chen, John C.
AU - Bavaria, Joseph E.
AU - Fedoruk, Lynn M.
AU - Munfakh, Nabil A.
AU - Sridhar, V.
AU - Scholz, Peter M.
AU - Pfeffer, Thomas A.
AU - Ye, Jian
N1 - Publisher Copyright: © 2022 The Author(s)
PY - 2022/12
Y1 - 2022/12
N2 - Objectives: The Prospective Randomized On-X Mechanical Prosthesis Versus St Jude Medical Mechanical Prosthesis Evaluation (PROSE) trial purpose was to investigate whether a current-generation mechanical prosthesis (On-X; On-X Life Technologies/Artivion Inc) reduced the incidence of thromboembolic-related complications compared with a previous-generation mechanical prosthesis (St Jude Medical Mechanical Prosthesis; Abbott/St Jude Medical). This second report documents the valve-related complications by individual prostheses and by Western and Developing populations. Methods: The PROSE trial study was conducted in 28 worldwide centers and incorporated 855 subjects randomized between 2003 and 2016. The study enrollment was discontinued on August 31, 2016. The study protocol, and analyses of 10 demographic variables and 24 risk factors were published in detail in 2021. Results: The total patient population (N = 855) included patients receiving an On-X valve (n = 462) and a St Jude Medical valve (n = 393). The overall freedom evaluation showed no differences at 5 years between the prostheses for thromboembolism or for valve thrombosis. There were also no differences in mortality. There were several differences between Developing and Western populations. The freedom relations at 5 years for mortality favored Western over Developing populations. Valve thrombosis was differentiated by position and site: aortic < mitral (P = .007) and Western < Developing (P = .005). In the mitral position there were no cases in Western populations, whereas there were 8 in Developing populations (P = .217). Conclusions: The On-X valve and St Jude Medical valve performed equally well in the study with no differences found. The only differentiation occurred with valve thrombosis in the mitral position more than the aortic position and occurring in Developing more than Western populations. The occurrence of valve thrombosis was also related to a younger population possibly due to anticoagulation compliance based on record review.
AB - Objectives: The Prospective Randomized On-X Mechanical Prosthesis Versus St Jude Medical Mechanical Prosthesis Evaluation (PROSE) trial purpose was to investigate whether a current-generation mechanical prosthesis (On-X; On-X Life Technologies/Artivion Inc) reduced the incidence of thromboembolic-related complications compared with a previous-generation mechanical prosthesis (St Jude Medical Mechanical Prosthesis; Abbott/St Jude Medical). This second report documents the valve-related complications by individual prostheses and by Western and Developing populations. Methods: The PROSE trial study was conducted in 28 worldwide centers and incorporated 855 subjects randomized between 2003 and 2016. The study enrollment was discontinued on August 31, 2016. The study protocol, and analyses of 10 demographic variables and 24 risk factors were published in detail in 2021. Results: The total patient population (N = 855) included patients receiving an On-X valve (n = 462) and a St Jude Medical valve (n = 393). The overall freedom evaluation showed no differences at 5 years between the prostheses for thromboembolism or for valve thrombosis. There were also no differences in mortality. There were several differences between Developing and Western populations. The freedom relations at 5 years for mortality favored Western over Developing populations. Valve thrombosis was differentiated by position and site: aortic < mitral (P = .007) and Western < Developing (P = .005). In the mitral position there were no cases in Western populations, whereas there were 8 in Developing populations (P = .217). Conclusions: The On-X valve and St Jude Medical valve performed equally well in the study with no differences found. The only differentiation occurred with valve thrombosis in the mitral position more than the aortic position and occurring in Developing more than Western populations. The occurrence of valve thrombosis was also related to a younger population possibly due to anticoagulation compliance based on record review.
UR - http://www.scopus.com/inward/record.url?scp=85138806185&partnerID=8YFLogxK
U2 - 10.1016/j.xjon.2022.07.011
DO - 10.1016/j.xjon.2022.07.011
M3 - Article
AN - SCOPUS:85138806185
SN - 2666-2736
VL - 12
SP - 51
EP - 70
JO - JTCVS Open
JF - JTCVS Open
ER -